期刊
BLOOD REVIEWS
卷 30, 期 3, 页码 157-167出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2015.10.003
关键词
Chimeric antigen receptor T cells; Adoptive immunotherapy
类别
资金
- Novartis
Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous enthusiasm. Twenty-five years after the concept was first proposed, major advances in molecular biology, virology, and good manufacturing practices (GMP)-grade cell production have transformed antibody-T cell chimeras from a scientific curiosity to a fact of life for academic cellular immunotherapy researchers and, increasingly, for patients. In this review, we explain the preclinical concept, outline how it has been translated to the clinic, and draw lessons from the first years of CART cell therapy for the practicing clinician. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据